← Leaderboards
Ethan Samuel Burstein
Acadia Pharmaceuticals, Inc.
$1,466,941
Attributed
$1,466,941
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $866.9K · FY2011–14$1M$750K$500K$250K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$1,466,941 · 1
By mechanism
U44$1,466,941 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAgonistAmes AssayAffectAnimal EfficacyAnimal ModelBiological AvailabilityCanis FamiliarisAnalgesicsCellsCharacteristicsChromosome AbnormalityChronicChung ModelConsciousControl TrialDependency (Psychology)DoseDrug CandidateCardiovascular SystemDrug InteractionsDrug KineticsDrug PackagingEfficacy Testing
Grant awards (3)
Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath$866,941
U44 · FY2014 · NS · contact PI
Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath$300,000
U44 · FY2012 · NS · contact PI
Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath$300,000
U44 · FY2011 · NS · contact PI